These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 37641650)

  • 21. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
    Tak YJ; Lee SY
    Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phentermine and topiramate extended-release for the obesity: new kids on the block.
    Katsi V; Marketou M; Kallistratos MS; Tousoulis D; Makris T; Manolis AJ; Vardas P; Kallikazaros I
    Recent Pat Cardiovasc Drug Discov; 2013 Apr; 8(1):35-41. PubMed ID: 23565717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacotherapy for obesity.
    Joo JK; Lee KS
    J Menopausal Med; 2014 Dec; 20(3):90-6. PubMed ID: 25580419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
    Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity.
    Hsia DS; Gosselin NH; Williams J; Farhat N; Marier JF; Shih W; Peterson C; Siegel R
    Diabetes Obes Metab; 2020 Apr; 22(4):480-491. PubMed ID: 31696603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination phentermine and topiramate for weight maintenance: the first Australian experience.
    Neoh SL; Sumithran P; Haywood CJ; Houlihan CA; Lee FT; Proietto J
    Med J Aust; 2014 Aug; 201(4):224-6. PubMed ID: 25164851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phentermine and topiramate extended release (Qsymia™): first global approval.
    Cameron F; Whiteside G; McKeage K
    Drugs; 2012 Oct; 72(15):2033-42. PubMed ID: 23039320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.
    Winslow DH; Bowden CH; DiDonato KP; McCullough PA
    Sleep; 2012 Nov; 35(11):1529-39. PubMed ID: 23115402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.
    Bays HE; Gadde KM
    Drugs Today (Barc); 2011 Dec; 47(12):903-14. PubMed ID: 22348915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phentermine-topiramate extended release for the dual treatment of obesity and sleep-related eating disorder: a case report.
    Grunvald E; DeConde J
    J Med Case Rep; 2022 Jan; 16(1):34. PubMed ID: 35081980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular Safety During and After Use of Phentermine and Topiramate.
    Ritchey ME; Harding A; Hunter S; Peterson C; Sager PT; Kowey PR; Nguyen L; Thomas S; Cainzos-Achirica M; Rothman KJ; Andrews EB; Anthony MS
    J Clin Endocrinol Metab; 2019 Feb; 104(2):513-522. PubMed ID: 30247575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
    Halpern B; Mancini MC
    Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
    Elkind-Hirsch KE; Chappell N; Seidemann E; Storment J; Bellanger D
    J Clin Endocrinol Metab; 2021 Sep; 106(10):3019-3033. PubMed ID: 34097062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.
    Gadde KM; Pritham Raj Y
    Curr Diab Rep; 2017 May; 17(5):34. PubMed ID: 28378293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case report of PLXNA4 variant associated with hyper-response to phentermine/topiramate pharmacotherapy: Potential genetic basis for superior weight loss response?
    Paszkowiak M; Dorand MF; Richards J
    Obes Pillars; 2023 Mar; 5():100059. PubMed ID: 37990741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SMART use of medications for the treatment of adolescent severe obesity: A sequential multiple assignment randomized trial protocol.
    Fox CK; Vock DM; Sherwood NE; Gross AC; Ryder JR; Bensignor MO; Bomberg EM; Sunni M; Bramante CT; Jacobs N; Raatz SJ; Kelly AS
    Contemp Clin Trials; 2024 Mar; 138():107444. PubMed ID: 38219798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration.
    Grabarczyk TR
    Pharmacotherapy; 2018 Jan; 38(1):19-28. PubMed ID: 29044720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).
    Davidson MH; Tonstad S; Oparil S; Schwiers M; Day WW; Bowden CH
    Am J Cardiol; 2013 Apr; 111(8):1131-8. PubMed ID: 23375187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pediatric Obesity: Complications and Current Day Management.
    Vajravelu ME; Tas E; Arslanian S
    Life (Basel); 2023 Jul; 13(7):. PubMed ID: 37511966
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.